Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Alvotech

< Previous 1 2 3 4 Next >
Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
From Alvotech
Via GlobeNewswire
Tickers ALVO
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Closing of Private Debt Financing
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Issues New Shares to Holders of Convertible Bonds
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and STADA add to strategic alliance through denosumab partnership
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Strategic Refinancing Agreement
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Alvotech
Via GlobeNewswire
Tickers ALVO RDY
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
From Alvotech
Via GlobeNewswire
Tickers ALVO
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Increase in Number of Own Shares
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Appoints Interim Chief Quality Officer
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
From Alvotech
Via GlobeNewswire
Tickers ALVO
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.